Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
SLS
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$14.98
▲ +12.89%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.39 - $15.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Up 525.9% over the trailing year
Total returns
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
Bear Case
1 risk
Growth
Revenue decline expected
Phase III trial results for GPS in acute myeloid leukemia expected to drive regulatory approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+221.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 12, 2026
Reported EPS of -$0.05 vs -$0.06 consensus (+16.7% surprise).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+16.7%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Maxim Group · Mar 12, 2026